Retatrutide vs Contrave: Next-Gen vs Current-Gen

Retatrutide and Contrave represent different generations of obesity pharmacotherapy. Contrave, a combination of naltrexone and bupropion approved in 2014, targets brain reward pathways and produces 5-8% weight loss. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produced 24.2% weight loss in Phase 2 trials — roughly three to five times more effective (Jastreboff et al., NEJM 2023). This comparison highlights how rapidly obesity medicine is evolving.

Mechanism Comparison

Contrave combines two established medications: naltrexone (an opioid antagonist used for addiction) and bupropion (an antidepressant/smoking cessation drug). Together, they modulate brain reward pathways to reduce food cravings and emotional eating. The theory is sound — obesity involves reward circuitry dysfunction — but the effect is modest because Contrave does not address the hormonal and metabolic drivers of obesity.

Retatrutide works through three hormone receptor pathways: GLP-1 slows gastric emptying and enhances satiety signals, GIP improves insulin sensitivity and fat metabolism, and glucagon increases energy expenditure and liver fat oxidation. This triple mechanism produces both reduced caloric intake and increased caloric burn, addressing obesity from multiple biological angles simultaneously.

Weight Loss Comparison

Side Effect Profiles

Contrave's side effects reflect its neurological mechanisms: nausea, headache, constipation, insomnia, dry mouth, and dizziness. It carries a black box warning for suicidal thoughts and behavior (from the bupropion component) and is contraindicated in patients with seizure disorders, eating disorders, or those using opioids.

Retatrutide's side effects are primarily GI-related: nausea (26%), diarrhea (22%), vomiting (13%), constipation (14%). It also produces mild transient heart rate increase and dysesthesia from the glucagon component. Retatrutide does not carry neuropsychiatric warnings and has no known seizure risk.

When Contrave Might Still Have a Role

Contrave's primary remaining role is for patients who cannot take GLP-1 medications due to contraindications (history of medullary thyroid cancer, MEN2 syndrome, or severe GI conditions) or for patients with significant emotional/binge eating patterns where the reward pathway modulation provides specific benefit. For patients who need an oral medication and refuse injections, Contrave is an option — though oral GLP-1 medications like orforglipron may soon eliminate this advantage.

Better Options Available Today

If you are currently taking Contrave or considering it, you should know that dramatically more effective medications are available at comparable prices. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month. These GLP-1 medications produce 15-22% weight loss — three to four times more than Contrave — with better metabolic benefits and fewer neuropsychiatric concerns. See how Trimi works.

Frequently Asked Questions

Is retatrutide better than Contrave for weight loss?

Significantly, yes. Retatrutide produces approximately 3-5 times more weight loss than Contrave (24.2% vs 5-8%) and provides far greater metabolic benefits. However, retatrutide is not yet FDA-approved.

Can you switch from Contrave to a GLP-1 medication?

Yes. Many patients are switching from Contrave to GLP-1 medications as they become more accessible. The transition is straightforward — discuss timing with your prescribing physician.

Can you take Contrave with semaglutide or tirzepatide?

Some physicians prescribe Contrave alongside GLP-1 medications as their mechanisms are complementary. However, this off-label combination adds side effects and cost. Discuss with your provider whether the modest additional benefit justifies the added medication.

Why is Contrave still prescribed?

Insurance coverage, familiarity, oral administration, and cost. As compounded GLP-1 medications become more affordable, Contrave prescribing is declining in favor of more effective hormonal treatments.